06-11-2012

AET BioTech, the separate biosimilars business within the generic drug developer AET (Alfred E Tiefenbacher) Group and BioXpress Therapeutics SA, a Swiss-based biotechnology company developing monoclonal antibody (MAb) biosimilars have entered into an agreement for the co-development of a ...

more

10-08-2012

The end of July 2012 proved exciting for the world of biosimilar manufacturers, according to GlobalData. However, for the regulatory officials worldwide it meant more uncertainty and unknowns about proper, global biosimilar guidelines. On July 23, 2012, South Korean biosimilar manufacturer ...

more

20-07-2012

Synthon announced that it has entered into a global license agreement with Amgen Inc. and Watson Pharmaceuticals, Inc. for Synthon’s trastuzumab, being developed as a biosimilar to Herceptin®, which is currently approved for treatment of breast cancer and gastric cancer. Earlier this year ...

more

18-06-2012

The global market for biosimilar drugs is due to come under attack from popular generic drugs, as governments fight to control rising healthcare expenditure, according to healthcare experts GBI Research.The report "Biosimilars in Emerging Economies - Advanced Recombinant Technology Platforms ...

more

Combined Biologics expertise of Merck and Dr. Reddy’s to deliver on promise of biosimilars

07-06-2012

Merck and Dr. Reddy’s Laboratories Ltd. announced a partnership to co-develop a portfolio of biosimilar compounds in oncology, primarily focused on monoclonal antibodies (MAbs). The partnership covers co-development, manufacturing and commercialization of the compounds around the globe, with ...

more

Synthon’s first truly biosimilar product now embarking on phase III study

26-03-2012

Synthon announced that it has successfully concluded a phase I clinical trial for trastuzumab, a biosimilar to Herceptin©, for treatment of breast cancer and gastric cancer. The company will now initiate a phase III clinical trial for trastuzumab, bringing an affordable alternative for ...

more

Huge Market Opportunity from Impending Patent Expiry of Blockbuster Biologics

22-03-2012

The expiration of patents and other intellectual property rights of biological innovators over the next decade opens the opportunity for biosimilars to enter the market and increase industry competition. However, biosimilars manufacturers require heavy investments, which are a major barrier ...

more

Seamlessly Integrated R&D, Production, Sales and Marketing Processes to Ensure Success in this High Growth Market

17-02-2012

The biosimilars manufacturing industry is at a nascent stage. However, the impending patent expiries of biologics are anticipated to result in the introduction of several new biosimilars and provide impetus to market development.New analysis from Frost & Sullivan, Analysis of European ...

more

20-01-2012

Sandoz announced that it has initiated two milestone Phase III clinical trials - one for biosimilar filgrastim (Amgen's Neupogen®) in the US market, the other for its global pegfilgrastim development program (Amgen's Neulasta®).The filgrastim study is to evaluate the efficacy and safety of ...

more

Patent Expiry of Several Key Blockbuster Drugs worth $ 150 billion between 2010 and 2017 Sets Stage for Entry of Generics Manufacturers

17-01-2012

The global generic pharmaceuticals market is likely to witness strong growth in the next few years owing to the patent expiration of key blockbuster drugs and the judicious cost containment efforts of governments and healthcare service providers worldwide. At the same time, the balance in ...

more